Haleon Cuts Outlook as Shares Drop
Haleon lowered its annual revenue growth forecast after missing third quarter estimates. Weaker cold medicine demand and regulatory issues in China pressured results.
Xurve View
Insights:
Xurve View
Haleon cut its annual organic revenue growth outlook to around 2.5% on Thursday morning, sending its shares down nearly 14%. The United Kingdom consumer health group lowered its forecast from 3% to 5% previously, missing market expectations of 3.2%. The guidance cut signals weaker consumer demand across key product lines in major international markets.
